Masakazu Yamamoto

Prof. Masakazu Yamamoto

Tokyo Women's Medical University
orcid

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015
Verified
Journal Article
Closed access
GWGo Wakabayashi
Go Wakabayashi
DCDaniel Cherqui
Daniel Cherqui
David GellerDavid Geller
David Geller
JBJoseph F Buell
Joseph F Buell
HKHironori Kaneko
Hironori Kaneko
SSSteven M Strasberg
Steven M Strasberg
The use of laparoscopy for liver surgery is increasing rapidly. The Second International Consensus Conference on Laparoscopic Liver Resections (LLR) was held in Morioka, Japan, from October 4 to 6, 2014 to evaluate the current status of laparoscopic liver surgery and to provide recommendations to aid its future development. Seventeen questions were addressed. The first 7 questions focused on outcomes that reflect the benefits and risks of LLR. These questions were addressed using the Zurich-Danish consensus conference model in which the literature and expert opinion were weighed by a 9-member jury, who evaluated LLR outcomes using GRADE and a list of comparators. The jury also graded LLRs by the Balliol Classification of IDEAL. The jury concluded that MINOR LLRs had become standard practice (IDEAL 3) and that MAJOR liver resections were still innovative procedures in the exploration phase (IDEAL 2b). Continued cautious introduction of MAJOR LLRs was recommended. All of the evidence available for scrutiny was of LOW quality by GRADE, which prompted the recommendation for higher quality evaluative studies. The last 10 questions focused on technical questions and the recommendations were based on literature review and expert panel opinion. Recommendations were made regarding preoperative evaluation, bleeding controls, transection methods, anatomic approaches, and equipment. Both experts and jury recognized the need for a formal structure of education for those interested in performing major laparoscopic LLR because of the steep learning curve.

22 October 2011 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Open access
PDF file
TBToru Beppu
Toru Beppu
YSYoshihiro Sakamoto
Yoshihiro Sakamoto
KHKiyoshi Hasegawa
Kiyoshi Hasegawa
GHGoro Honda
Goro Honda
KTKuniya Tanaka
Kuniya Tanaka
TTTadahiro Takada
Tadahiro Takada
Background/purpose: The aim of this study was to create a nomogram to predict the disease‐free survival of patients with colorectal liver metastases treated with hepatic resection.Methods: Perioperative factors were assessed in 727 hepatectomized patients with colorectal liver metastases between 2000 and 2004 at the 11 institutions of the “Project Committee of the Liver” in the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery. A nomogram was developed as a graphical representation of a stepwise Cox proportional hazards regression model.Results: Perioperative mortality was 0.55%. Disease‐free and overall survival rates were 31.2 and 63.8% at 3 years, 27.2 and 47.7% at 5 years, and 24.7 and 38.5% at 10 years, respectively. Six preoperative factors were selected to create the nomogram for disease‐free survival: synchronous metastases, 3 points; primary lymph node positive, 3 points; number of tumors 2–4, 4 points and ≥5, 9 points; largest tumor diameter >5 cm, 2 points; extrahepatic metastasis at hepatectomy, 4 points, and preoperative carbohydrate antigen 19‐9 level >100, 4 points. The estimated median disease‐free survival time was easily calculated by the nomogram: >8.4 years for patients with 0 points, 1.9 years for 5 points, 1.0 years for 10 points, and the rates were lower than 0.6 years for patients with more than 10 points.Conclusions: This nomogram can easily calculate the median and yearly disease‐free survival rates from only 6 preoperative variables. This is a very useful tool to determine the likelihood of early recurrence and the necessity for perioperative chemotherapy in patients with colorectal liver metastases after hepatic resection.

4 December 2010 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Open access
PDF file
KUKazuhisa Uchiyama
Kazuhisa Uchiyama
Masakazu YamamotoMasakazu Yamamoto
Masakazu Yamamoto
HYHiroki Yamaue
Hiroki Yamaue
SAShun‐Ichi Ariizumi
Shun‐Ichi Ariizumi
TATaku Aoki
Taku Aoki
TTTadahiro Takada
Tadahiro Takada
Background/purpose: The aim of this study was to clarify the prognostic factors of intrahepatic cholangiocarcinoma (ICC) following hepatectomy and to examine the impact of lymph node metastasis on survival. This study was therefore carried out as a Project Study of the Japanese Society of Hepato‐Biliary‐Pancreatic Surgery.Methods: Three hundred and forty‐one patients who underwent hepatectomy for ICC between 1995 and 2004 at the 9 institutions of the Medical University Hospitals were analyzed retrospectively. Multivariate regression analyses and a Kaplan–Meyer analysis were performed to identify prognostic factors.Results: Pathological lymph node metastasis was one of the significant factors affecting overall survival (hazard ratio 2.10,p < 0.001) based on the multivariate analysis. Among the patients who underwent extended lymphadenectomy beyond the hepatoduodenal ligament, the median survival of 121 patients with nodal involvement was 12.2 months. Only seven patients with nodal involvement have survived for more than 4 years.Conclusions: In the present study, preoperative carbohydrate antigen (CA) 19‐9, intrahepatic metastasis, and nodal involvement were the significant independent predictors of poor prognosis by multivariate analysis. Further prospective studies may thus be needed to confirm these findings, because this study has a limitation in that it was a retrospective study with multicenter data collection.

23 February 2022 in Liver Cancer
Verified
Journal Article
Open access
PDF file
SKShoji Kubo
Shoji Kubo
HSHiroji Shinkawa
Hiroji Shinkawa
YAYoshinari Asaoka
Yoshinari Asaoka
TITatsuya Ioka
Tatsuya Ioka
HIHiroshi Igaki
Hiroshi Igaki
Masakazu YamamotoMasakazu Yamamoto
Masakazu Yamamoto
This paper presents the first version of clinical practice guidelines for intrahepatic cholangiocarcinoma (ICC) established by the Liver Cancer Study Group of Japan. These guidelines consist of 1 treatment algorithm, 5 background statements, 16 clinical questions, and 1 clinical topic, including etiology, staging, pathology, diagnosis, and treatments. Globally, a high incidence of ICC has been reported in East and Southeast Asian countries, and the incidence has been gradually increasing in Japan and also in Western countries. Reported risk factors for ICC include cirrhosis, hepatitis B/C, alcohol consumption, diabetes, obesity, smoking, nonalcoholic steatohepatitis, and liver fluke infestation, as well as biliary diseases, such as primary sclerosing cholangitis, hepatolithiasis, congenital cholangiectasis, and Caroli disease. Chemical risk factors include thorium-232, 1,2-dichloropropane, and dichloromethane. CA19-9 and CEA are recommended as tumor markers for early detection and diagnostic of ICC. Abdominal ultrasonography, CT, and MRI are effective imaging modalities for diagnosing ICC. If bile duct invasion is suspected, imaging modalities for examining the bile ducts may be useful. In unresectable cases, tumor biopsy should be considered when deemed necessary for the differential diagnosis and drug therapy selection. The mainstay of treatment for patients with Child-Pugh class A or B liver function is surgical resection and drug therapy. If the patient has no regional lymph node metastasis (LNM) and has a single tumor, resection is the treatment of choice. If both regional LNM and multiple tumors are present, drug therapy is the first treatment of choice. If the patient has either regional LNM or multiple tumors, resection or drug therapy is selected, depending on the extent of metastasis or the number of tumors. If distant metastasis is present, drug therapy is the treatment of choice. Percutaneous ablation therapy may be considered for patients who are ineligible for surgical resection or drug therapy due to decreased hepatic functional reserve or comorbidities. For unresectable ICC without extrahepatic metastasis, stereotactic radiotherapy (tumor size ≤5 cm) or particle radiotherapy (no size restriction) may be considered. ICC is generally not indicated for liver transplantation, and palliative care is recommended for patients with Child-Pugh class C liver function.

9 September 2017 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Open access
PDF file
MKMasaki Kaibori
Masaki Kaibori
MKMasanori Kon
Masanori Kon
TKTomoki Kitawaki
Tomoki Kitawaki
TKTakayuki Kawaura
Takayuki Kawaura
KHKiyoshi Hasegawa
Kiyoshi Hasegawa
Masakazu YamamotoMasakazu Yamamoto
Masakazu Yamamoto
Background: The aim of the present study was to compare the prognostic impact of anatomic resection (AR) versus non‐anatomic resection (NAR) on patient survival after resection of a single hepatocellular carcinoma (HCC).Methods: To control for confounding variable distributions, a 1‐to‐1 propensity score match was applied to compare the outcomes of AR and NAR. Among 710 patients with a primary, solitary HCC of <5.0 cm in diameter that was resectable by either AR or NAR from 2003 to 2007 in Japan and Korea, 355 patients underwent NAR and 355 underwent AR of at least one section with complete removal of the portal territory containing the tumor.Results: Overall survival (OS) was better in the AR than NAR group (hazard ratio 1.67, 95% confidence interval 1.28–2.19, P < 0.001) while disease‐free survival showed no significant difference. Significantly fewer patients in the AR than NAR group developed intrahepatic HCC recurrence and multiple intrahepatic recurrences. Patients with poorly differentiated HCC who underwent AR had improved disease‐free survival and OS.Conclusions: Anatomic resection decreases the risk of tumor recurrence and improves OS in patients with a primary, solitary HCC of <5.0 cm in diameter.

1 January 2014 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
AAAtsushi Aruga
Atsushi Aruga
NTNobuhiro Takeshita
Nobuhiro Takeshita
YKYoshihito Kotera
Yoshihito Kotera
RORyuji Okuyama
Ryuji Okuyama
NMNorimasa Matsushita
Norimasa Matsushita
Masakazu YamamotoMasakazu Yamamoto
Masakazu Yamamoto
The prognosis of patients with advanced biliary tract cancer (BTC) is extremely poor and only a few standard treatments are available for this condition. We performed a phase I trial to investigate the safety, immune response and anti-tumor effect of vaccination with three peptides derived from cancer-testis antigens. This study was conducted as a phase I trial. Nine patients with advanced BTC who had unresectable tumors and were refractory to standard chemotherapy were enrolled. Three HLA-A*2402 restricted epitope peptides-cell division cycle associated 1 (CDCA1), cadherin 3 (CDH3) and kinesin family member 20A (KIF20A)-were administered subcutaneously, and the adverse events and immune response were assessed. The clinical effects observed were the tumor response, progression-free survival (PFS) and overall survival (OS). The three-peptide vaccination was well-tolerated up to a dose of 3 mg per peptide (9 mg total). No grade 3 or 4 adverse events were observed after vaccination. Peptide-specific T cell immune responses were observed in all patients and stable disease was observed in 5 of 9 patients. The median PFS and OS were 3.4 and 9.7 months. The Grade 2 injection site reaction and continuous vaccination after PD judgment appeared to be prognostic of OS. Multiple-peptide vaccination was well tolerated and induced peptide-specific T-cell responses. This study was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN- CTR000003229 ).